Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 176 - 200 of 1585 in total

Succinylcholine

Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter acetylcholine (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its...
Approved

Phenylbutyric acid

Phenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone. It is used to treat genetic metabolic syndromes, neuropathies, and urea cycle disorders.[L386,L42105]
Approved
Investigational

Tolvaptan

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Flecainide

Flecainide is a Class I anti-arrhythmic agent like encainide and propafenone. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA...
Approved
Withdrawn
Matched Categories: … Narrow Therapeutic Index Drugs ... MATE 1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Belinostat

Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies...
Approved
Investigational
Matched Description: … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma …
Matched Categories: … Narrow Therapeutic Index Drugs ... UGT1A1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Docetaxel

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel.[A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …

Dienestrol

Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of...
Approved
Investigational

Loncastuximab tesirine

Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
Approved
Investigational
Matched Description: … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients …

Racepinephrine

Racepinephrine is a racemic mixture consisting of d-DB00668 and l-DB00668 enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingredient in...
Approved

Polysorbate 80

Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer in many foods, including bread, cake mix, salad dressing, shortening oil and...
Approved

Finerenone

Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.[A236519,L34739] Patients with kidney...
Approved
Investigational

Ibritumomab tiuxetan

Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and...
Approved
Investigational
Matched Categories: … Therapeutic Radiopharmaceuticals ... Various Therapeutic Radiopharmaceuticals …

Digoxin

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also...
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... BSEP/ABCB11 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Lorlatinib

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors …

Pralatrexate

Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have...
Approved
Investigational
Matched Description: … [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein ... [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate …
Matched Categories: … Narrow Therapeutic Index Drugs …

Digitoxin

A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Siponimod

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Idarubicin

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Cyclothiazide

As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter....
Approved
Matched Description: … It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance …

Cyanocobalamin

Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria , and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-,...
Approved
Nutraceutical
Matched Mixtures name: … UNICAP-THERAPEUTIC FILM TABLET, 30 ADET …

Paliperidone

Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin...
Approved
Matched Description: … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination …

Pimozide

A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994,...
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Clarithromycin

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug...
Approved
Matched Description: … Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein ... peptidyl transferase activity and interferes with amino acid translocation during the translation and protein …
Matched Categories: … Protein Synthesis Inhibitors …

Theophylline

A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly...
Approved
Matched Categories: … Narrow Therapeutic Index Drugs ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Temozolomide

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these...
Approved
Investigational
Matched Categories: … Narrow Therapeutic Index Drugs ... P-glycoprotein substrates with a Narrow Therapeutic Index …
Displaying drugs 176 - 200 of 1585 in total